Pharmacokinetics And Tolerability Of Subcutaneous Administration Of PF 04236921 In Healthy Volunteers

Pfizer

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: PF-04236921

Study type: Interventional

Funder types: Industry

Identifiers

NCT01166555

EudraCT 2010-019770-32

B0151004

Details and patient eligibility

About

This study will evaluate the safety, tolerability, and pharmacokinetics of PF-04236921 administered as a single subcutaneous dose in healthy volunteers.

Full description

Tolerability and Pharmacokinetics of subcutaneously administered dose of PF-04236921 in healthy volunteers

Enrollment: 10 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy males between 18-55 years, inclusive.
• Healthy females of non-childbearing potential between 18 and 55 years, inclusive.

Exclusion criteria

• Evidence or history of clinically significant disease.
• Females of childbearing potential.

Trial design

10 participants in 1 patient group

1

Experimental group

Treatment:

Drug: PF-04236921